Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Saved in:
| Title: | Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. |
|---|---|
| Authors: | Feldt-Rasmussen, Ulla1 (AUTHOR) ufeldt@rh.dk, Hughes, Derralynn2 (AUTHOR), Sunder-Plassmann, Gere3 (AUTHOR), Shankar, Suma4 (AUTHOR), Nedd, Khan5 (AUTHOR), Olivotto, Iacopo6 (AUTHOR), Ortiz, Damara7 (AUTHOR), Ohashi, Toya8 (AUTHOR), Hamazaki, Takashi9 (AUTHOR), Skuban, Nina10 (AUTHOR), Yu, Julie10 (AUTHOR), Barth, Jay A.10 (AUTHOR), Nicholls, Kathleen11 (AUTHOR) |
| Source: | Molecular Genetics & Metabolism. Sep2020, Vol. 131 Issue 1/2, p219-228. 10p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10967192 |
|---|---|
| DOI: | 10.1016/j.ymgme.2020.07.007 |
